Chronic myelomonocytic leukemia (CMML) is a type of leukemia that is categorized by the abnormal production or maturation of immune cells.
The drug Dacogen (decitabine) provides anticancer activity by disrupting cellular processes so that cancer cells stop growing. Although it is not currently approved for CMML, clinical trials are evaluating its effectiveness for the treatment of a variety of cancers.
A clinical trial conducted by M.D. Anderson to evaluate Dacogen in the treatment of CMML was published in the journal Cancer. Out of the 19 patients studied, 58 percent achieved a complete disappearance of detectable cancer.
The researchers did conclude that Dacogen appears to be an effective treatment option for patients diagnosed with Chronic myelomonocytic leukemia.
